2. Academic Validation
  3. Intranasal Seletracetam in a Patient with Reading Epilepsy: First-in-Human Use to Prevent Reflex Seizures

Intranasal Seletracetam in a Patient with Reading Epilepsy: First-in-Human Use to Prevent Reflex Seizures

  • Ann Neurol. 2025 Dec 29. doi: 10.1002/ana.78128.
Matthias J Koepp 1 2,  Kai-Nicolas Poppert 3,  Thomas Felder 4,  Aljoscha Thomschewski 3 5,  Sandra Lafenthaler 3,  Pavel Klein 6,  Alexander Rotenberg 7,  Wolfgang Löscher 8,  Chris Rundfeldt 9,  Eugen Trinka 3 5 10
Affiliations

Affiliations

  • 1 Department of Neurology, National Hospital for Neurology and Neurosurgery, Queens Square, London, UK.
  • 2 Department of Clinical and Experimental Epilepsy, UCL Queen Square Institute of Neurology, University College London, London, UK.
  • 3 Department of Neurology, Neurocritical Care and Neurorehabilitation, Christian Doppler University Hospital, Centre of Cognitive Neuroscience, Paracelsus Medical University, Salzburg, Member of EpiCARE, Salzburg, Austria.
  • 4 Department of Laboratory Medicine, Paracelsus Medical University, Salzburg, Austria.
  • 5 Neuroscience Institute, Christian Doppler University Hospital, Centre of Cognitive Neuroscience, Paracelsus Medical University, Salzburg, Austria.
  • 6 Mid-Atlantic Epilepsy and Sleep Center, Bethesda, MD, USA.
  • 7 Department of Neurology, Boston Children's Hospital and Harvard Medical School, Boston, MA, USA.
  • 8 Translational Neuropharmacology Lab, NIFE, Department of Experimental Otology of the ENT Clinics, Hannover Medical School, Hannover, Germany.
  • 9 Drug Consulting Network, Coswig, Germany.
  • 10 Karl Landsteiner Institute for Clinical Neuroscience, Salzburg, Austria.
PMID: 41459805 DOI: 10.1002/ana.78128
Abstract

We report the first human use of intranasal seletracetam (SEL) to prevent reflex seizures. A patient with epilepsy with reading-induced seizures on levetiracetam (3,000 mg/day) continued to experience reading-induced focal seizures with preserved consciousness. Detectable in serum within 2 minutes of intranasal administration, 30 mg seletracetam delayed seizure onset from 1:56 (placebo) to 4:17 minutes post-stimulus onset. A second 30 mg dose fully prevented seizures during 25 minutes of reading. Electroencephalogram (EEG) spike-frequency declined dose-dependently (3.1/min at placebo to 1.6/min after second dose), with reduced spike-propagation on magnetoencephalography (MEG). Our findings support SEL as a promising non-benzodiazepine acute seizure prevention and provide insight into reflex seizure dynamics. ANN NEUROL 2025.

Figures
Products